{
  "id": "altimmune-secures-75m-for-phase-3-liver-therapy-trials",
  "title": "Altimmune secures $75m for Phase 3 liver therapy trials",
  "summary": "Altimmune raises $75 million to advance pemvidutide, a promising therapy tackling serious liver and metabolic diseases. For most, liver disease is a background noise – a shrug-worthy diagnosis until it precipitates a catastrophic systemic failure. Yet metabolic dysfunction-associated steatohepatitis (MASH) is increasingly the silent engine of the modern metabolic crisis. It is an insidious pathology, […] The post Altimmune secures $75m for Phase 3 liver therapy trials appeared first on Longevity.Technology.",
  "url": "https://longevity.technology/news/altimmune-secures-75m-for-phase-3-liver-therapy-trials/",
  "source": "Longevity.Technology",
  "author": "Kyle Umipig",
  "category": "news",
  "publishedAt": "2026-01-30T16:58:57.000Z",
  "fetchedAt": "2026-02-04T10:49:05.818Z",
  "relevanceScore": 0.2,
  "matchedKeywords": [
    "longevity"
  ],
  "relatedProducts": [],
  "type": "web",
  "savedAt": "2026-02-04T10:49:05.889Z"
}